Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
Identifieur interne : 000344 ( PascalFrancis/Checkpoint ); précédent : 000343; suivant : 000345Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
Auteurs : Daniel Weintraub [États-Unis] ; Juergen Koester [Allemagne] ; Marc N. Potenza [États-Unis] ; Andrew D. Siderowf [États-Unis] ; Mark Stacy [États-Unis] ; Valerie Voon [Canada] ; Jacqueline Whetteckey [États-Unis] ; Glen R. Wunderlich [Canada] ; Anthony E. Lang [Canada]Source :
- Archives of neurology : (Chicago) [ 0003-9942 ] ; 2010.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Context: An association between dopamine-replacement therapies and impulse control disorders (ICDs) in Parkinson disease (PD) has been suggested in preliminary studies. Objectives: To ascertain point prevalence estimates of 4 ICDs in PD and examine their associations with dopamine-replacement therapies and other clinical characteristics. Design: Cross-sectional study using an a priori established sampling procedure for subject recruitment and raters blinded to PD medication status. Patients: Three thousand ninety patients with treated idiopathic PD receiving routine clinical care at 46 movement disorder centers in the United States and Canada. Main Outcome Measures: The Massachusetts Gambling Screen score for current problem/pathological gambling, the Minnesota Impulsive Disorders Interview score for compulsive sexual behavior and buying, and Diagnostic and Statistical Manual of Mental Disorders research criteria for binge-eating disorder. Results: An ICD was identified in 13.6% of patients (gambling in 5.0%, compulsive sexual behavior in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3%), and 3.9% had 2 or more ICDs. Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P<.001). Impulse control disorder frequency was similar for pramipexole and ropinirole (17.7% vs 15.5%; OR, 1.22; 95% CI, 0.94-1.57; P=.14). Additional variables independently associated with ICDs were levodopa use, living in the United States, younger age, being unmarried, current cigarette smoking, and a family history of gambling problems. Conclusions: Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD. This association represents a drug class relationship across ICDs. The association of other demographic and clinical variables with ICDs suggests a complex relationship that requires additional investigation to optimize prevention and treatment strategies.
Affiliations:
- Allemagne, Canada, États-Unis
- Caroline du Nord, Connecticut, Ontario, Pennsylvanie
- Philadelphie, Toronto
- Université de Toronto
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:10-0257883Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients</title><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1><s2>Philadelphia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Philadelphia Veterans Affairs Medical Center</s1><s2>Philadelphia</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Koester, Juergen" sort="Koester, Juergen" uniqKey="Koester J" first="Juergen" last="Koester">Juergen Koester</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Boehringer Ingelheim Pharma GmbH & Co KG</s1><s2>Ingelheim</s2><s3>DEU</s3><sZ>2 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co KG</wicri:noRegion><wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co KG</wicri:noRegion></affiliation></author><author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Yale University School of Medicine</s1><s2>New Haven, Connecticut</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1><s2>Philadelphia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Duke University Medical Center</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>6 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name><affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Boehringer Ingelheim Pharmaceuticals Inc</s1><s2>Ridgefield, Connecticut</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Boehringer Ingelheim (Canada) Ltd</s1><s2>Burlington, Ontario</s2><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Boehringer Ingelheim (Canada) Ltd</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>6 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0257883</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0257883 INIST</idno><idno type="RBID">Pascal:10-0257883</idno><idno type="wicri:Area/PascalFrancis/Corpus">000437</idno><idno type="wicri:Area/PascalFrancis/Curation">000840</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000344</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000344</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients</title><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1><s2>Philadelphia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Philadelphia Veterans Affairs Medical Center</s1><s2>Philadelphia</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Koester, Juergen" sort="Koester, Juergen" uniqKey="Koester J" first="Juergen" last="Koester">Juergen Koester</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Boehringer Ingelheim Pharma GmbH & Co KG</s1><s2>Ingelheim</s2><s3>DEU</s3><sZ>2 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co KG</wicri:noRegion><wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co KG</wicri:noRegion></affiliation></author><author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Yale University School of Medicine</s1><s2>New Haven, Connecticut</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1><s2>Philadelphia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Duke University Medical Center</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>6 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name><affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Boehringer Ingelheim Pharmaceuticals Inc</s1><s2>Ridgefield, Connecticut</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Boehringer Ingelheim (Canada) Ltd</s1><s2>Burlington, Ontario</s2><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Boehringer Ingelheim (Canada) Ltd</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>6 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author></analytic><series><title level="j" type="main">Archives of neurology : (Chicago)</title><title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title><idno type="ISSN">0003-9942</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Archives of neurology : (Chicago)</title><title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title><idno type="ISSN">0003-9942</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cross sectional study</term><term>Human</term><term>Impulse control disorder</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Trouble du contrôle des impulsions</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Etude transversale</term><term>Homme</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Context: An association between dopamine-replacement therapies and impulse control disorders (ICDs) in Parkinson disease (PD) has been suggested in preliminary studies. Objectives: To ascertain point prevalence estimates of 4 ICDs in PD and examine their associations with dopamine-replacement therapies and other clinical characteristics. Design: Cross-sectional study using an a priori established sampling procedure for subject recruitment and raters blinded to PD medication status. Patients: Three thousand ninety patients with treated idiopathic PD receiving routine clinical care at 46 movement disorder centers in the United States and Canada. Main Outcome Measures: The Massachusetts Gambling Screen score for current problem/pathological gambling, the Minnesota Impulsive Disorders Interview score for compulsive sexual behavior and buying, and Diagnostic and Statistical Manual of Mental Disorders research criteria for binge-eating disorder. Results: An ICD was identified in 13.6% of patients (gambling in 5.0%, compulsive sexual behavior in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3%), and 3.9% had 2 or more ICDs. Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P<.001). Impulse control disorder frequency was similar for pramipexole and ropinirole (17.7% vs 15.5%; OR, 1.22; 95% CI, 0.94-1.57; P=.14). Additional variables independently associated with ICDs were levodopa use, living in the United States, younger age, being unmarried, current cigarette smoking, and a family history of gambling problems. Conclusions: Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD. This association represents a drug class relationship across ICDs. The association of other demographic and clinical variables with ICDs suggests a complex relationship that requires additional investigation to optimize prevention and treatment strategies.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0003-9942</s0></fA01><fA02 i1="01"><s0>ARNEAS</s0></fA02><fA03 i2="1"><s0>Arch. neurol. : (Chic.)</s0></fA03><fA05><s2>67</s2></fA05><fA06><s2>5</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients</s1></fA08><fA11 i1="01" i2="1"><s1>WEINTRAUB (Daniel)</s1></fA11><fA11 i1="02" i2="1"><s1>KOESTER (Juergen)</s1></fA11><fA11 i1="03" i2="1"><s1>POTENZA (Marc N.)</s1></fA11><fA11 i1="04" i2="1"><s1>SIDEROWF (Andrew D.)</s1></fA11><fA11 i1="05" i2="1"><s1>STACY (Mark)</s1></fA11><fA11 i1="06" i2="1"><s1>VOON (Valerie)</s1></fA11><fA11 i1="07" i2="1"><s1>WHETTECKEY (Jacqueline)</s1></fA11><fA11 i1="08" i2="1"><s1>WUNDERLICH (Glen R.)</s1></fA11><fA11 i1="09" i2="1"><s1>LANG (Anthony E.)</s1></fA11><fA14 i1="01"><s1>University of Pennsylvania School of Medicine</s1><s2>Philadelphia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="02"><s1>Philadelphia Veterans Affairs Medical Center</s1><s2>Philadelphia</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="03"><s1>Boehringer Ingelheim Pharma GmbH & Co KG</s1><s2>Ingelheim</s2><s3>DEU</s3><sZ>2 aut.</sZ></fA14><fA14 i1="04"><s1>Yale University School of Medicine</s1><s2>New Haven, Connecticut</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="05"><s1>Duke University Medical Center</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>6 aut.</sZ><sZ>9 aut.</sZ></fA14><fA14 i1="07"><s1>Boehringer Ingelheim Pharmaceuticals Inc</s1><s2>Ridgefield, Connecticut</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Boehringer Ingelheim (Canada) Ltd</s1><s2>Burlington, Ontario</s2><s3>CAN</s3><sZ>8 aut.</sZ></fA14><fA20><s1>589-595</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>2048B</s2><s5>354000181757200100</s5></fA43><fA44><s0>0000</s0><s1>© 2010 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>35 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>10-0257883</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Archives of neurology : (Chicago)</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Context: An association between dopamine-replacement therapies and impulse control disorders (ICDs) in Parkinson disease (PD) has been suggested in preliminary studies. Objectives: To ascertain point prevalence estimates of 4 ICDs in PD and examine their associations with dopamine-replacement therapies and other clinical characteristics. Design: Cross-sectional study using an a priori established sampling procedure for subject recruitment and raters blinded to PD medication status. Patients: Three thousand ninety patients with treated idiopathic PD receiving routine clinical care at 46 movement disorder centers in the United States and Canada. Main Outcome Measures: The Massachusetts Gambling Screen score for current problem/pathological gambling, the Minnesota Impulsive Disorders Interview score for compulsive sexual behavior and buying, and Diagnostic and Statistical Manual of Mental Disorders research criteria for binge-eating disorder. Results: An ICD was identified in 13.6% of patients (gambling in 5.0%, compulsive sexual behavior in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3%), and 3.9% had 2 or more ICDs. Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P<.001). Impulse control disorder frequency was similar for pramipexole and ropinirole (17.7% vs 15.5%; OR, 1.22; 95% CI, 0.94-1.57; P=.14). Additional variables independently associated with ICDs were levodopa use, living in the United States, younger age, being unmarried, current cigarette smoking, and a family history of gambling problems. Conclusions: Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD. This association represents a drug class relationship across ICDs. The association of other demographic and clinical variables with ICDs suggests a complex relationship that requires additional investigation to optimize prevention and treatment strategies.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Trouble du contrôle des impulsions</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Impulse control disorder</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Trastorno control impulso</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Etude transversale</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Cross sectional study</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Estudio transversal</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Human</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0><s5>10</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>172</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>Canada</li><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Connecticut</li><li>Ontario</li><li>Pennsylvanie</li></region><settlement><li>Philadelphie</li><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name></region><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name></country><country name="Allemagne"><noRegion><name sortKey="Koester, Juergen" sort="Koester, Juergen" uniqKey="Koester J" first="Juergen" last="Koester">Juergen Koester</name></noRegion></country><country name="Canada"><region name="Ontario"><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name></region><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000344 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000344 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:10-0257883
|texte= Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
}}
| This area was generated with Dilib version V0.6.29. |  |